Upgrade to SI Premium - Free Trial

BofA on Alnylam (ALNY): 'AI-enabled diagnostics will help increase diagnosis rates'

March 24, 2026 3:10 PM
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $460.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments